| Ticker Symbol: | GENZ |
|---|---|
| Exchange: | NASD |
| Contact Info: | 500 Kendall Street Cambridge MA 02142 617 252-7500 |
| CEO/President: | Henri A. Termeer |
| Industry: | Medical - Biomedical / Standard Industry Code: 2836 |
| Description: | Genzyme Corporation is a global biotechnology company dedicated to making a major positive impact on the lives of people with serious diseases. The company\'s broad product portfolio is focused on rare genetic disorders, renal disease, and osteoarthritis, and includes an industry-leading array of diagnostic products and services. Genzyme\'s commitment to innovation continues today with research into novel approaches to cancer, heart disease, and other areas of unmet medical need. |
| Shares Outstanding: | 267,310 (000) | Market Value: | 17,352,300 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 86.92% | Number of Inst.Shareholders: | 2.80% |
| Last Quarter Sales: | 1171.13 ($Mil.) | Last Quarter Net Income: | 69.56 ($Mil.) |
| Last Quarter EPS: | 0.81 | P/E Ratio: | 19 |
| Most Recent Earnings: | 0.98 on 07/23/08 | Earnings Per Share: | 1.63 |
| Most Recent Split: | 2-1 on 06/04/01 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |


| AMGEN | +0.50 | 53.80 | |
| GILEAD SCIENCES | -10.20 | 42.65 | |
| GENENTECH INC | +6.50 | 81.18 | |
| CELGENE CP | -10.00 | 61.46 | |
| BIOGEN IDEC INC | -32.40 | 47.13 |
